索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]王京京 詹成创 苏梦琦 薛红杰.伊布替尼相关性心房颤动研究进展[J].国际心血管病杂志,2020,02:92-96.
点击复制

伊布替尼相关性心房颤动研究进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2020年02期
页码:
92-96
栏目:
综述
出版日期:
2020-03-29

文章信息/Info

Title:
-
作者:
王京京 詹成创 苏梦琦 薛红杰
150001 哈尔滨医科大学附属第一医院心血管内科
Author(s):
-
关键词:
伊布替尼;  心房颤动;  靶向药物;  不良反应
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2020.02.008
文献标识码:
-
摘要:
心房颤动(房颤)需要严格的抗栓治疗,由于血液指标受累,血液系统肿瘤患者房颤的抗栓治疗策略更需要合理规范。伊布替尼是新一代抗肿瘤靶向药物,研究表明其能导致伊布替尼相关性房颤(IRAF)的发生,明确IRAF的发生机制有助于IRAF的预防和规范化治疗。该文介绍IRAF的发生机制及防治策略进展。
Abstract:
-

参考文献/References

[ 1 ] Tang CPS, Mcmullen J, Tam C. Cardiac side effects of bruton tyrosine kinase(BTK)inhibitors[J]. Leuk Lymphoma, 2018, 59(7):1554-1564.
[ 2 ] Thorp BC, Badoux X. Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management[J]. Leuk Lymphoma, 2018, 59(2):311-320.
[ 3 ] Shaikh H, Khattab A, Faisal MS, et al. Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-a single institution experience and a review of literature[J]. J Oncol Pharm Pract, 2019, 25(5):1265-1270.
[ 4 ] Levy I, Polliack A, Tadmor T. Five ibrutinib-associated side effects that all clinicians should be aware of[J]. Acta Haematol, 2019, 141(4):254-255.
[ 5 ] Paydas S. Management of adverse effects/toxicity of ibrutinib[J]. Crit Rev Oncol Hematol, 2019, 136:56-63.
[ 6 ] Rhodes J, Mato A, Sharman JP. Monitoring and management of toxicities of novel B cell signaling agents[J]. Curr Oncol Rep, 2018, 20(6):49.
[ 7 ] Bernardeschi P, Pirrotta MT, Del Rosso A, et al. Sudden ventricular fibrillation and death during ibrutinib therapy-a case report[J]. Eur J Haematol, 2019, 103(4):442-443.
[ 8 ] Gülsaran SK, Baysal M, Demirci U, et al. Late onset left ventricular dysfunction and cardiomyopathy induced with ibrutinib[J]. J Oncol Pharm Pract, 2019:1078155219852146.
[ 9 ] Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis[J]. Haematologica, 2018, 103(5):874-879.
[10] Fradley MG, Gliksman M, Emole J, et al. Rates and risk of atrial arrhythmias in patients treated with ibrutinib compared with cytotoxic chemotherapy[J]. Am J Cardiol, 2019, 124(4):539-544.
[11] Rhea IB, Lyon AR, Fradley MG. Anticoagulation of cardiovascular conditions in the cancer patient: review of old and new therapies[J]. Curr Oncol Rep, 2019, 21(5):45.
[12] Leong DP, Caron F, Hillis C, et al. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis[J]. Blood, 2016, 128(1):138-140.
[13] Brown JR, Moslehi J, O'brien S, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials[J]. Haematologica, 2017, 102(10):1796-1805.
[14] Ezad S, Khan AA, Cheema H, et al. Ibrutinib-related atrial fibrillation: a single center Australian experience[J]. Asia Pac J Clin Oncol, 2019, 15(5):e187-e190.
[15] Baptiste F, Cautela J, Ancedy Y, et al. High incidence of atrial fibrillation in patients treated with ibrutinib[J]. Open heart, 2019, 6(1):e001049.
[16] Gribben JG, Bosch F, Cymbalista F, et al. Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice[J]. Br J Haematol, 2018, 180(5):666-679.
[17] Mato AR, Clasen S, Pickens P, et al. Left atrial abnormality(LAA)as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia[J]. Cancer Biol Ther, 2018, 19(1):1-2.
[18] Reda G, Fattizzo B, Cassin R, et al. Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study[J]. J Hematol Oncol, 2018, 11(1):79.
[19] Lentz R, Feinglass J, Ma S, et al. Risk factors for the development of atrial fibrillation on ibrutinib treatment[J]. Leuk Lymphoma, 2019, 60(6):1447-1453.
[20] Stühlinger MC, Weltermann A, Staber P, et al. Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk[J]. Wien Klin Wochenschr, 2020, 132(3/4):97-109.
[21] Pretorius L, Du XJ, Woodcock EA, et al. Reduced phosphoinositide 3-kinase(p110alpha)activation increases the susceptibility to atrial fibrillation[J]. Am J Pathol, 2009, 175(3):998-1009.
[22] Ganatra S, Sharma A, Shah S, et al. Ibrutinib-associated atrial fibrillation[J]. JACC Clinl Electrophysio, 2018, 4(12):1491-1500.
[23] McMullen JR, Boey EJ, Ooi JY, et al. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling[J]. Blood, 2014, 124(25):3829-3830.
[24] Shafaattalab S, Lin E, Christidi E, et al. Ibrutinib displays Atrial-Specific toxicity in human stem cell-derived cardiomyocytes[J]. Stem Cell Reports, 2019, 12(5):996-1006.
[25] Tuomi JM, Xenocostas A, Jones DL. Increased susceptibility for atrial and ventricular cardiac arrhythmias in mice treated with a single high dose of ibrutinib[J]. Can J Cardiol, 2018, 34(3):337-341.
[26] Jiang L, Li L, Ruan Y, et al. Ibrutinib promotes atrial fibrillation by inducing structural remodeling and Calcium dysregulation in the atrium[J]. Heart Rhythm, 2019, 16(9):1374-1382.
[27] Aguilar C. Ibrutinib-related bleeding: pathogenesis, clinical implications and management[J]. Blood Coagul Fibrinolysis, 2018, 29(6):481-487.
[28] Jeyakumar D, O'brien S. B cell receptor inhibition as a target for CLL therapy[J]. Best Pract Res Clin Haematol, 2016, 29(1):2-14.
[29] Kapelios CJ, Bonou MS, Diamantopoulos P, et al. Ibrutinib-related atrial fibrillation: therapeutic challenges[J]. J Oncol Pharm Pract, 2019, 25(5):1258-1260.
[30] Brown JR. How I treat CLL patients with ibrutinib[J]. Blood, 2018, 131(4):379-386.
[31] Boriani G, Corradini P, Cuneo A, et al. Practical management of ibrutinib in the real life: focus on atrial fibrillation and bleeding[J]. Hematol Oncol, 2018, 36(4):624-632.
[32] Shatzel JJ, Olson SR, Tao DL, et al. Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies[J]. J Thromb Haemost, 2017, 15(5):835-847.
[33] Stephens DM, Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia[J]. Blood, 2019, 133(12):1298-1307.

备注/Memo

备注/Memo:
基本项目:黑龙江省教育厅资助项目(12541306)
作者单位:150001 哈尔滨医科大学附属第一医院心血管内科
通信作者:薛红杰,E-mail:xuehj@163.com
更新日期/Last Update: 2020-03-30